Back to results
US 2017/0304313 A1Published application
Therapeutic Combination For The Treatment Of Cancer
AssigneeNovartis AG
InventorsDale Porter, Nafeeza Hafeez
Life of this patent
Estimating the term…
Abstract
This invention relates to a pharmaceutical combination comprising (a) an EGFR inhibitor and (b) a FGFR inhibitor, particularly for use in the treatment of a cancer. This invention also relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating or preventing a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto.
Claims23
A pharmaceutical combination comprising (a) a compound of formula I
- (R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide, or a pharmaceutically acceptable salt thereof, and (b) a FGFR inhibitor.
Dependencies are inferred from the claim text.